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1. Introduction  
Over the last few decades and particularly in the present economic context, the distribution 
of economic resources has been a concern addressed by governmental and corporate 
scientific policy, which has either benefitted only part of the scientific and technological 
community or furthered certain lines of research. The pharmaceutical industry in particular 
has had to confront not only this situation, but also ongoing internationalisation, supported 
by the relentless advances in communication technologies. 
Until the nineteen eighties, industry internationalisation, in terms of R&D, was a marginal 
matter, not only for economics theory and business in general, but also for governments and 
the other organisations involved. Globalisation began to acquire importance after the mid 
nineteen nineties, although not all manufacturing industries have experienced the same 
degree of R&D internationalisation. The pharmaceutical industry, for one, pioneered this 
more universal approach to research and development (Noisi, 1999). 
Contrary to the widely held opinion according to which R&D internatianlisation is the fruit 
of domestic innovation in many industries, pharmaceutical constitutes an exception. Indeed, 
international innovation intensifies the industry’s R&D (Patel and Pavitt, 2000), whereas in 
other lines of business domestic innovation is the driver. In addition to internationalising its 
R&D, the pharmaceuticals industry has increased its research spending exponentially in 
recent years (Congressional Budget Office, 2006). 
A number of earlier papers studied the bibilometric characteristics of the pharmacological 
publications generated as a result of the R&D effort in places such as the United States 
(Narin and Rozek, 1988), India (Kaur and Gupta, 2009; Gupta and Kaur, 2009) or the Middle 
East (Biglu and Omidi, 2010). Others stressed the contribution of pharmaceutical firms to 
scientific knowledge (Koening, 1983; McMillan and Hamilton, 2000; Rafols, et al. 2010; 
Perianes-Rodríguez, et al. 2011). The assessment of the international impact of scientific 
papers is a present, but not a new concern: it has been a frequent object of study since the 
nineteen eighties. The use of scientific indicators for several decades to characterise research 
by subject area, country or institution has confirmed that, although they have their 
limitations, they are the only suitable tool for scientific assessment (Braun T et al., 1985). 
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The purpose of this chapter is to analyse international research in “pharmacology, 
toxicology and pharmaceutics” (hereafter pharmacology) on the basis of the scientific papers 
listed in the Scopus multidisciplinary database. This primary objective is reached by 
answering the following questions (in the section on results). What weight does the subject 
area “pharmacology, toxicology and pharmaceutics” carry in world-wide science? What is 
the percentage contribution made by the various regions of the world to the subject area 
“pharmacology, toxicology and pharmaceutics”? Can certain regions be identified as leaders 
on that basis, as in other scientific contexts? Are emerging countries present in the field? Do 
the most productive countries also publish the largest number of journals? What features 
characterise the scientific output of companies that publish pharmacological papers?  
2. Methodology  
2.1 Database 
The possible sources of information for scientometric research include multi-disciplinary 
databases such as Thomson Reuters’ Web of Science, Elsevier’s Scopus and resources such 
as Google Scholar, as well as specialised services such as Medline. These sources analyse 
research results in the form of scientific papers published in international journals and their 
subsequent citation by the rest of the scientific community. 
Scopus, the Elsevier database created in 2004, lists over 18 000 journals edited by over 5 000 
publishers1. When it first appeared, it was analysed by many authors and compared to other 
resources in a whole stream of papers (Fingerman, 2005; LaGuardia, 2005). It was chosen for 
the present study because of its broad subject area and linguistic coverage; in the 
understanding that world-wide scientific production is more fully represented in Scopus 
than in other databases (Sciverse Scopus, 2011). In addition, as a resource suitable for 
research conducted after 1996, it is particularly apt for a subject area such as pharmacology 
(Gorraiz and Schloegl, 2008). 
Scopus’ strong points as a source of information are reinforced by an open access, on-line 
tool known as SCImago Journal and Country Rank (SJR, 2007). As its name infers, this 
system of scientific information, drawing from Scopus contents from 1996 to 2010, ranks 
journals and countries using data intended for world-wide scientific assessment. The tool 
provides open access to both data and indicators by region or country, with international 
coverage. It proved to be particularly useful for the aims pursued in the present study.  
2.2 Indicators 
Two sets of bibliometric indicators were used in this study: one to determine the 
quantitative characteristics of scientific output and the other to analyse its quality, i.e., the 
qualitative characteristics of citations and journals (Rehn, 2007). The indicators included in 
each group are described below. 
This study calculated the number of scientific papers published by the units analysed (world, 
region, country or industry) over the time span defined. All of the various possible types of 
papers (such as articles, reviews and notes to the editor,) were included in the output indicator. 
                                                                 
1 Available from http://www.info.sciverse.com/scopus/scopus-in-detail/facts/. 20/08/2011 
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When papers were co-authored by researchers from institutions in different countries, a 
complete computational approach was adopted. The growth rate, when provided, indicates 
the rise or decline in world-wide output in 2009 with respect to the baseline year, 1996.  
A number of indicators were used to obtain an approximate view of the quality of world 
scientific output in the field of pharmacology. The number of citations received refers to the 
total number of times papers published by the unit analysed were cited during the period 
studied. This indicator provides an overview of the scientific impact of the articles published 
by the unit in question. The number of citations per paper was calculated as the mean number of 
citations received by all the papers published by the unit analysed in the period studied.  
The domestic citations were separated from the total to determine the proportion of the 
output that was used as a reference in the same geographic area (region or country) and 
consequently, by simple subtraction, the proportion involving knowledge transfer to other 
areas. The results are shown as the percentage of the citations used for research conducted 
in the same geographic area. The normalised citation indicator is the relative number of times 
papers produced by a specific unit were cited, compared to the world-wide mean for papers 
of the same type, age and subject area. 
While citations denote the subsequent use of papers once published, the references list the 
literature cited in papers published by a journal at any given time. The number of references 
per paper was found by dividing the total number of references by the number of papers 
published by the unit. 
A country’s H-index, in turn, specifies the number of papers (h) produced in that country 
and receiving at least h citation. It relates a country’s scientific productivity (output) to its 
scientific impact (citations). The international collaboration indicator is the percentage of 
papers with author affiliations in more than one country. This indicator measures 
institutions’ international networking capacity. In this chapter a journal’s % output in Q1 is 
the percentage of scientific papers published by an institution in what are classified as the 
most influential journals in the respective category, i.e., the periodicals in the first quartile or 
Q1, the upper 25 %, based on their SJR value.  
Another qualitative indicator used, homonymous with the aforementioned scientific 
information system (SCImago Journal and Country Rank), was the Scimago Journal Rank 
(SJR), used as an alternative to the traditional impact factor (I.F.). This indicator, which 
measures the visibility of the journals in the Scopus® database, is established by the 
SCImago2 research team on the grounds of the well-known Google PageRankTM algorithm. 
It differs from the I.F. in two ways: citations are computed over 3 rather than 2 years; and 
article citations are weighted, with citations in more visible or prominent journals carrying 
greater weight than citations in lower-ranking journals (González-Pereira et al., 2009). 
3. Results  
3.1 World-wide science and pharmacology 
World-wide scientific output, as listed in the Scopus database for the period running from 
1996 to 2009, came to 21 100 138 papers. The total citations received by those papers during the 
                                                                 
2 http://www.scimago.es/. 20.08.2011 
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same period amounted to 217 388 448, for a mean of 10.03 citations per paper. The absolute 
numbers for pharmacology, as one of the 27 subject areas established by Scopus, were logically 
much smaller. The totals were 564 914 papers and 6 266 408 citations. The mean number of 
citations in pharmacology was therefore higher than the world average, at 11.09. The growth 
rate for this subject area was 4.76 %, reflecting the growth in its scientific output.  
Figure 1 shows the percentage contribution of the Scopus subject areas to world-wide 
scientific output during the period studied. Medicine played a predominant role in the 
international scientific scenario, with a mean yearly contribution of over 20 %. Decision 
science and dentistry stood at the other extreme, with a mean yearly output of 0.35 %, 
shown on the figure as very thin lines. The mean yearly contribution of pharmacology to 
international scientific output in the period was 2.7 %, shown in red on the right half of the 
graph. When pooled, all the subject areas with relative outputs of under 4 %, which include 
pharmacology, earth and planet sciences, immunology and microbiology, accounted for 
34.83 % of the scientific papers published world-wide. 
 
Fig. 1. World output by subject areas (%) (Scopus, 1996-2009) 
3.2 Pharmacology by region  
While scientific output by region is an important indicator to determine regional 
contributions to pharmacology, quantitative information alone is incomplete and must be 
supplemented with data on the impact of these papers on the scientific community. Table 1 
gives the vales of some of the indicators described earlier for a number of regions, along 
with colour bar graphs for readier interpretation. 
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Region Output Citations Domestic citations %Domestic citations Citations per paper
North America 155373 2714951 2209503 81.38 17.47
Western Europe 159512 2383236 1671534 70.14 14.94
Asia 113741 1095409 626665 57.21 9.63
Eastern Europe 21951 178157 57830 32.46 8.12
Latin America 18122 164264 78623 47.86 9.06
Pacific Region 11802 161126 45651 28.33 13.65
Middle East 10256 105817 27329 25.83 10.32
Southern Africa 2167 23987 7406 30.88 11.07
Central Africa 2035 11101 4650 41.89 5.46
Northen Africa 827 7559 1808 23.92 9.14  
Table 1. Pharmacological scientific output, citations and domestic citations by region 
(Scopus, 1996-2009) 
The behaviour of the domestic citations indicator merits comment. In North America, these 
citations accounted for over 80 % percent of the total. The number of domestic citations was 
likewise very high in Western Europe; in both regions most of the citations were found in 
articles published in the same country as the paper cited. Consequently, in these two 
regions, the large number of domestic citations led to an inordinately large number of total 
citations.  
The regions with smaller numbers of citations also had a smaller proportion of domestic 
citations. In other words, their output was acknowledged primarily by other regions, while 
domestic citations were less frequent. The region that best illustrates this observation is 
Northern Africa, where only 23.92 % of the citations received were domestic.  
The number of citations per paper was also highest in North America and Western Europe, 
with the Pacific Region ranking a close third. Central Africa’s low scientific output in 
pharmacology was only scantly acknowledged, with only 5.46 citations per paper on 
average. Asia, Eastern Europe, Latin America and Northern Africa had similar citations per 
paper values, which ranged from 8 to 9. 
The pharmacological output by regions over the period 1996 to 2009 is shown in Figure 2. 
The three most productive regions in that period were Western Europe (red), North 
America (blue) and Asia (green). Asia had a higher growth rate in the latter years of the 
period and was the most productive region in 2009. This rise may have been the result of 
greater participation in the pharmacology, particularly in countries that in those years began 
to adopt a very active role in the field. 
3.3 Countries and pharmacology 
The basic unit for the regions listed above was defined as the individual country. A total of 
194 countries published pharmacological research in the period studied. The analysis 
conducted of their output provided greater insight into the values found for the regional 
indicators.  
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Fig. 2. Pharmacological scientific output by region (Scopus, 1996-2009) 
The ten most productive countries accounted for around 71 % of world-wide pharmacological 
output in the period studied. These ten countries are listed in Table 2, which shows their total 
output in the period, the number of total and domestic citations received, the citations per 
paper and the H index. The list is headed by the United States, which had the largest output 
and number of citations, although the number per paper should be interpreted bearing in 
mind the impact of the large number of domestic citations identified. At 293, its H index was 
likewise high, indicating that 293 papers were cited in 293 other articles. 
Table 3 ranks the countries whose overall data for the entire period are given in Table 2, 
year by year across the period. Grey shading indicates that the country changed its position 
from the preceding year and maroon shading that the country joined the top ten in the year 
in question.  
The regional study showed the enormous progress in Asia in the latter years of the period. 
That growth was the result of greater participation in the subject area by Asian countries. 
Although until 2005 Japan was the second largest producer in pharmacology, from 2006 
onward it was overtaken by an emerging neighbour: China. In the three earliest years China 
ranked tenth; in the intermediate years it gradually climbed to higher positions and finally 
reached second place in 2006. While still among the most productive countries, Japan's 
position slid, denoting its tendency to contribute less and less to pharmacological output. In 
the last year of the series, 2009, four of the ten most productive countries were Asian (China, 
India, Japan and South Korea).  
The United States maintained its lead throughout the period. That leadership and Canada’s 
contribution, from lower but still productive positions, made North America the sole region 
with an output comparable to Asia’s in the latter years. All the other most productive 
countries in pharmacology were from Western Europe: United Kingdom, Germany, Italy 
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and France, and the Netherlands and Spain in some years. Only one Latin American country 
was among the most productive during the period: Brazil, in 2007.  
Country Output Citations Domestic 
citations
Citations per 
paper
H Index
United States 154941 2516137 1221126 17.38 293
Japan 47322 543692 164265 11.38 139
United Kingdom 40531 644728 143933 16.9 195
China 36079 178269 80870 6.34 84
Germany 34443 442517 106046 13.49 157
India 23323 144862 59885 9.22 91
Italy 22593 304775 75527 14.88 128
France 21925 320578 64831 15.28 148
Canada 18667 297798 61608 17.18 143
Spain 14232 165910 41389 12.66 101  
Table 2. Pharmacological scientific output, domestic citations, citations per document and H 
index for the 10 most productive countries (Scopus, 1996-2009) 
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
USA USA USA USA USA USA USA USA USA USA USA USA USA USA
Japan Japan Japan Japan Japan Japan Japan Japan Japan Japan China China China China
U.K. U.K. U.K. U.K. U.K. U.K. U.K. U.K. U.K. China Japan Japan U.K. India
Germany Germany Germany Germany Germany Germany Germany Germany Germany U.K. U.K. U.K. Japan U.K.
France France France France France France Italy China China Germany Germany Germany India Japan
Italy Italy Italy Italy Italy Italy France France Italy Italy India India Germany Germany
Canada Canada Canada Canada China China China Italy France India Italy Italy Italy Italy
Spain Spain Netherlands China Canada Canada Canada Canada Canada France France France France France
Netherlands Netherlands Spain Netherlands Spain Netherlands India India India Canada Canada Canada Canada Canada
China China China Spain India Spain Netherlands Spain Netherlands Spain Spain Brazil South Korea South Korea
 
Table 3. Country position by output (Scopus, 1996-2009) 
Figures 3 and 4 show the relationship between international collaboration and citations per 
paper in countries publishing at least 1 000 papers. The position occupied by the countries in 
each region is shown in both figures, but only Western European and North American 
countries are depicted in Figure 3. All the Asian, Eastern European and Latin American 
countries are shown in Figure 4, although only the BRIC countries (Brazil, Russia, India, 
China) are labelled.  
 
Pharmacology  346 
 
Fig. 3. International collaboration and citations per paper in North American and Western 
European countries (www.scimagoir.com), 2003-2009. 
 
Fig. 4. International collaboration and citations per paper in BRIC countries 
(www.scimagoir.com), 2003-2009. 
The country in Figure 3 with the smallest number of citations per paper and least intense 
international collaboration was Turkey. With 6.18 citations per paper and an international 
co-authorship percentage of 16.12, it stood at the low end of its region, Western Europe, and 
had lower citation values than Latin America or Eastern Europe. In Western Europe, 
Sweden and Belgium were the two countries both in that region and the world with the 
highest international collaboration indices and a mean of 12 citations per paper. Both, as 
well as other countries, also had higher values than the USA (in terms of international 
collaboration) and Canada. 
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Measuring their scientific status in terms of citations per paper and international 
collaboration values, the BRIC countries still have room for improvement. Three of those 
four countries were positioned very close to the origin on the graph. Of the four, only Brazil 
showed values close to the results recorded for Turkey.  
3.4 Pharmacology in journals 
The analysis of the journals that published pharmacological papers included the data for the 
periodicals that published at least one such paper in 2009. Under that criterion, a total of 482 
journals were identified, 61 of which had been recently added to the database and 
consequently lacked the data needed to calculate their SJR. 
Of the remaining 421 (that had published more than one paper and had an SJR index), 110 
were edited in the United States, although a fair number were also published in other 
countries: Netherlands (87), United Kingdom (75), Germany (25), China (12), India (12), 
Japan (11), Spain (11), France (8), Switzerland (7) and New Zealand (6).  
The remaining journals were published in a total of 33 countries, each with less than six 
journals.  
10 top journals by SJR value SJR Ouput (2009)
Citations 
(3years)
Citations per 
paper (2years)
Refs
Ref per 
doc
Country
Annual Review of Pharmacology and Toxicology 3.56 19 1429 22.94 2367 124.58 United States
Pharmacological Reviews 3.3 19 1433 17.16 6531 343.74 United States
Nature Reviews Drug Discovery 2.68 202 5827 15.67 7865 38.94 United Kingdom
Trends in Pharmacological Sciences 1.64 84 2588 9.56 5718 68.07 Netherlands
Drug Resistance Updates 1.52 16 530 11.79 1836 114.75 United States
DNA Repair 1.44 169 2237 4.15 10528 62.3 Netherlands
Pharmacology and Therapeutics 1.22 104 3367 9.23 20152 193.77 United States
Current Opinion in Pharmacology 1.14 117 2138 7.57 6206 53.04 Netherlands
Advanced Drug Delivery Reviews 1.1 143 4030 12.34 15219 106.43 Netherlands
10 top journals by total documents in 2009 SJR Ouput (2009)
Citations 
(3years)
Citations per 
paper  
(2years)
Refs
Ref per 
doc
Country
Bioorganic and Medicinal Chemistry Letters 0.21 1546 10591 2.72 39742 25.71 Netherlands
Pharmaceutical Journal 0.03 1058 124 0.1 972 0.92 United Kingdom
Deutsche Apotheker Zeitung 0.02 967 11 0.02 1440 1.49 Germany
Bioorganic and Medicinal Chemistry 0.2 910 7859 2.88 34194 37.58 Netherlands
Chemosphere 0.15 905 11704 3.41 32003 35.36 Netherlands
European Journal of Pharmacology 0.27 619 6875 2.76 26762 43.23 Netherlands
British Journal of Pharmacology 0.6 616 6819 5.29 28480 46.23 United Kingdom
Medical Hypotheses 0.12 612 1835 1.55 16902 27.62 United States
Japanese Journal of Cancer and Chemotherapy 0.03 611 163 0.09 889 1.45 Japan
International Journal of Pharmaceutics 0.19 528 5930 3.33 17075 32.34 Netherlands  
Table 4. Pharmacology journals: SJR, output, citations, citations per paper, references, 
references per paper and country of publication (Scopus), 2009 
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The large and unwieldy original table was abbreviated to build Table 4, which gives the 
values for only the journals with the 10 highest SJR and the 10 scientific journals that 
published the largest number of pharmacological articles in the last year of the series. Note 
that none of these journals appears on both lists.  
Of the scientific journals with the highest SJR, two were published in the US, Annual Review 
of Pharmacology and Toxicology and Pharmacological Review, and one in the United Kingdom, 
Nature Reviews and Drug Discovery. These three journals had SJR scores of 3.56, 3.3 and 2.68, 
respectively. That means that they received large numbers of citations, but also that since 
they are weighted by journal prestige to calculate the indicator, those citations appeared in 
other high quality journals. Neither of the US journals was very productive, with only 19 
papers each in 2009, compared to a much larger output by the English periodical, which 
published a total of 202 articles.  
The scientific journals with the highest output in pharmacology were The Netherlands’ 
Bioorganic and Medicinal Chemistry Letters, with 1 546 papers, followed by the UK’s 
Pharmaceutical Journal, with 1 058 and Germany’s Deutsche Apotheker Zeitung, with 967. Their 
SJR indices were lower than for the journals mentioned in the preceding paragraph, however, 
with scores of 0.21, 0.03 and 0.02, respectively. In other words, in the period calculated for the 
SJR index (three years), either the absolute number of citations received by this group of more 
productive journals was very low or the citations were published in lower quality journals. 
Each country’s contribution to pharmacological scientific output can be analysed from two 
perspectives: as specified earlier, by the contribution made by its scientists through their 
published papers, or by the journals edited in the country. These two factors are compared 
in Figure 5. Each country’s scientific output is shown in red and its publishing activity in 
blue. Many countries, such as the United States, show similar percentages for both types of 
contribution, while in others the values vary widely. A case in point is The Netherlands, 
whose scientific output was a mere 2 % while its journals published over 20 % of the 
pharmacological articles.  
 
Fig. 5. Percentage of pharmacology-related journals and papers published by country 
(Scopus, 2009) 
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3.5 Scientometric indicators for pharmaceutical companies  
The pharmaceutical industry, in addition to being one of the most profitable, is also one of 
the most globalised and fastest growing lines of business. Moreover, its large investment in 
research makes it an innovation-intensive activity. This innovation is the result of the direct 
or indirect interaction of a large number of actors: different types of companies, research 
institutes, financial institutions, public bodies and authorities, public and private 
universities, research centres, regulating bodies, governments, health systems, consumers 
and physicians, to name a few. 
The industry comprises three categories of companies. The first covers (primarily North 
American and European) multinational companies that operate globally and invest huge 
sums in R&D, which is centralised in some cases and decentralised with laboratories in 
many countries and on many continents in others. The second category consists of small 
companies that supply their domestic markets with drugs that require no substantial R&D 
investment. The third includes firms that specialise in biotechnology and invest 
considerable sums in research despite their small size. 
In 2010, biopharmaceutical companies invested an estimated 67.4 billion dollars in pursuit 
of new drugs (Figure 6). The total R&D spending by Pharmaceutical Research and 
Manufacturers of America (PhRMA) members, including industry majors such as 
AstraZeneca, Bayer, Boehringer, Ingelheim, Bristol-Myers, Squibb, Eli Lilly, Genzyme, 
GlaxoSmithKline, Hoffmann-La Roche, Merck, Novartis, Pfizer, and Sanofi-Aventis, as well 
as non-members, are shown in the figure.  
  
Fig. 6. Biopharmaceutical company R&D and PhRMA member R&D: 1995–2010 (Sources: 
Burrill and Company, analysis for PhRMA, 2005–2011 (Includes PhRMA research associates 
and non-members); PhRMA, PhRMA Annual Member Survey, 1996-2010)  
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Figure 7 shows the R&D spending by PhRMA members in and outside the United States. 
The total R&D investment by pharmaceutical companies has continued to rise. In 2010 
PhRMA members invested 49.4 billion dollars, up 6 % from 2009 and 90 % since 2009.  
PhRMA members spent most of their R&D budgets (76.1 %) in the United States, Western 
Europe (16.6 %) and Japan (1.5 %), while spreading the rest across other countries around 
the world (PhRMA, 2011). 
 
Fig. 7. R&D spending by Pharmaceutical Research and Manufacturers of America (PhRMA) 
members, 1975-2010 (PhRMA, 2011) 
Bibliometric indicators can be constructed for the pharmaceutical industry on the grounds of 
the research results made public by the authors. As noted earlier, the industry has been 
gradually internationalising its high research and innovation potential since the mid 
nineteen seventies (McMillan and Hamilton, 2000).  
The values of the bibliometric parameters for the pharmaceutical majors are given in Table 
5. The data, which cover a seven-year period and are based on these companies’ research 
publications, reveal a number of interesting differential characteristics. The ranking criterion 
followed was scientific output defined as the number of papers published in 2003-2009, 
initially disaggregated, although some of the companies listed had parent-subsidiary 
relationships. 
The first significant result was the volume of scientific papers published by these 
companies. These elite, all of whose members published at least 125 papers in the period 
considered, was headed by the Pfizer headquarters site, which averaged 353 papers yearly 
throughout the period, followed by Merck with a yearly mean of 251.  
The second statistic of interest was the citations per paper, which ranged from fairly low 
(7.86 for Dow Chemical Co., 8.47 for the Indian firm Dr Reddy´s and 9.26 for Sanofi-Aventis 
GmbH in Germany) to very high values (18.47 for Astra Zeneca in the United Kingdom and 
0
5000
10000
15000
20000
25000
30000
35000
40000
19
75
19
77
19
79
19
81
19
83
19
85
19
87
19
89
19
91
19
93
19
95
19
97
19
99
20
01
20
03
20
05
20
07
20
09
M
il
li
o
n
 d
o
ll
ar
s
R&D spending in the USA R&D spending outside in the USA
 
A Multi-Level Analysis of World Scientific Output in Pharmacology 351 
18.21 for Hoffmann-La Roche in Switzerland). These findings suggest substantial differences 
in the visibility or quality of firms’ scientific knowledge. 
Organisation Country Output
Citations 
per paper
International 
collaboration
Normalised 
Citation
% Output in 
Q1
Pfizer Inc. USA 2476 12.4 18.54 1.55 79.36
Merck & Co., Inc. USA 1759 14.34 18.08 1.74 83.63
Eli Lilly and Company USA 820 16.13 25.24 1.68 81.1
GlaxoSmithKline. United States USA 788 15.17 29.7 1.77 86.68
GlaxoSmithKline. United 
Kigdom GBR 781 13.76 42.77 1.74 85.66
Bristol-Myers Squibb Company USA 677 12.97 13 1.58 87.59
Novartis CHE 595 16.82 66.72 1.8 77.98
Abbott Laboratories United 
States USA 571 14.75 12.61 1.65 88.27
Amgen USA 497 12.27 16.9 1.59 77.46
F. Hoffmann-La Roche. Ltd. USA 452 14.81 21.46 1.84 83.19
Pfizer Ltd GBR 379 14.8 43.54 1.73 79.16
Bayer AG DEU 362 10.46 36.74 1.34 64.36
Johnson & Johnson 
Pharmaceutical Research USA 356 13.45 18.54 1.68 87.64
AstraZeneca R&D SWE 294 14.64 57.82 1.8 87.07
F. Hoffmann-La Roche. Ltd. CHE 272 18.21 55.15 1.86 83.09
Sanofi-Aventis. S.A. FRA 224 15.64 43.75 1.55 66.52
Laboratoires SERVIER FRA 200 17.16 37.5 1.71 91.5
Novartis Pharma SA. East 
Hanover USA 192 16.2 34.9 1.89 73.96
AstraZeneca Pharmaceuticals. LP USA 188 15.77 30.85 1.69 75
Sanofi-Aventis Deutschland 
GmbH DEU 167 9.26 26.35 0.95 57.49
Schering-Plough Research 
Institute USA 165 12.8 12.73 1.46 86.67
AstraZeneca GBR 161 18.47 40.37 1.81 77.64
Novartis Institutes for 
Biomedical Research USA 161 12.93 60.87 1.77 84.47
Laboratoires Pierre Fabre. S.A. FRA 155 10.18 23.23 1.17 81.94
Novo Nordisk A/S DNK 153 12.77 46.41 1.32 77.12
Dr. Reddy's Laboratories Ltd. IND 150 8.47 7.33 0.88 59.33
H. Lundbeck A/S DNK 150 18.11 45.33 1.73 91.33
GlaxoSmithKline. Italy ITA 127 11.52 66.14 1.57 81.89
Dow Chemical Company USA 125 7.86 34.4 0.9 66.4  
Table 5. Bibliometric performance indicators for pharmaceutical firms, 2003-2009 
(www.scimagoir.com)  
Pharmaceuticals is generally agreed to be one of the industries whose research is most 
intensely internationalised, defining that to mean the proportion of the research conducted 
outside the headquarters country. The industry’s business has become more international 
since the nineteen nineties as a result of the convergence of a number of processes. New 
industrial activities have cropped up around biotechnological research, primarily in the US; 
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market dynamics with a view to capitalising on research incentives has favoured the 
location of new laboratories in different countries; global excellence centres with research 
responsibilities have been created; and inter- and intra-firm networking has been intensified. 
When companies were ranked in descending order of the percentage of their papers 
involving international collaboration, two different patterns emerged, one for European and 
the other for North American companies. The percentages were higher in the former than in 
the latter. Several explanations can be given for this difference between countries on the two 
sides of the Atlantic. The United States is the critical location for pharmaceutical alliances as a 
result of the quality of the research conducted there, but especially of the size of its research 
base, i.e., the number and size of universities, companies and research departments. Other 
factors that distinguish the European and US include the latter’s easy financing and marketing 
terms and fairly large number of start-up incubators and venture capitalists. 
The result is that companies based in the US have lower percentages of internationally co-
authored papers than European companies: Abbott Laboratories 12.67 %, Schering-Plough 
Research Institute, 12.73 %, Bristol-Myers Squibb Company, 13 %.  
Switzerland’s Novartis, by contrast, co-authored 66.72 % of its papers with other countries. 
Its US subsidiary had a collaboration rate of 69.87 %, while the figure for the French firm 
Sanofi-Aventis was 43.75 %. 
The final indicator analysed was normalised citation, which measures a company’s impact 
on the scientific community as a whole and compares the quality of the research conducted 
by organisations of different sizes. The highest score was obtained by Swiss Novartis’ North 
American subsidiary, with a mean citation value 89 % higher than the world-wide mean 
(1.89). It was followed by its parent company, which had a mean citation value 86 % higher 
than the world-wide mean, and the Swiss subsidiary of North America’s F. Hoffman La 
Roche, with a score of 84 %. The lowest values were recorded for Dow Chemical’s 
pharmaceuticals division (US) and the Dr. Reddy laboratories in India, whose citation 
values were below the international average. 
4. Conclusions 
This chapter reports on a multi-level analysis of scientific results in pharmacology. The 
findings confirmed that despite its scant weight in world-wide science, pharmacological 
scientific output is characterised by high quality and has citation per paper values higher 
than the mean for international scientific output as a whole. 
Two regions of the world have traditionally occupied the leading positions in terms of 
pharmacological scientific output, North America and Western Europe. Moreover, the 
impact of this output is high, measured in terms of citations in other papers. When only 
citations outside the home region are considered, however, other regions, such as Northern 
Africa, prove to have higher values. The regions with the largest absolute number of 
citations also have the highest percentage of domestic citations. By contrast, since the 
regions with smaller numbers of citations in absolute terms receive fewer domestic citations, 
the acknowledgement coming primarily from countries outside their own region carries 
much heavier weight. 
 
A Multi-Level Analysis of World Scientific Output in Pharmacology 353 
During the period studied, certain emerging countries such as Brazil or India joined the list 
of top ten producers, while China, which was already on the list, climbed almost to the 
summit. As might be expected, the countries in the most productive regions occupied the 
highest positions throughout the period analysed, but the appearance of these BRIC 
countries should prompt reflection on their scientific potential in the field of pharmacology. 
The most productive journals, i.e., the ones that publish the largest number of 
pharmacological articles, do not generally earn high SJR impact values. These values are 
attained by journals publishing smaller numbers of papers. Consequently, journal quality 
and the number of papers published are inversely related. An analysis relating papers 
published and journals edited in each country showed that intense pharmacological 
publishing is not necessarily attendant upon the presence of numerous researchers working 
in the field (The Netherlands). US publishing in pharmacology, by contrast, is as 
predominant in the area as its research community.  
Companies carry specific weight in pharmacology. Their investment and innovative 
capacity are mirrored by the scientific results attained, primarily by US and European 
pharmaceutical laboratories. 
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